Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive rally sent Hims stock catapulting more than 200% over a month, its future now looks as uncertain as its semaglutide-making days.
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising rates of type 2 diabetes and obesity.
Ro Khanna (D-Calif.) posted a video on TikTok informing his 400,000 followers of “breaking news” that “the Trump administration announced that Medicare will stop covering telehealth on April 1st,” and calling for opposition to “stand up to these Medicare cuts.
Medicare Part D spending for 10 selected diabetes drugs in the USA totaled $35.8 billion in 2023, an increase of 364% from 2019.
The lawsuit, filed by the Outsourcing Facilities Association , FarmaKeio Custom Compounding and North American Custom Laboratories in the U.S. District Court for the Northern District of Texas, argues that the FDA acted arbitrarily and is depriving patients of critical medication, according to court documents reviewed by Becker's.
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Semaglutide use in patients with Type 2 diabetes was associated with reduced postoperative complications after 90 days, according to a study in the March 2025 i